Under the exemption, companies may issue unregistered common stock to public investors "in exchange for one or more bona fide outstanding securities, claims or property interests," provided all the terms and conditions are approved by a court or authorized government agency...In clinical trials, 14 percent of the prior null responders with cirrhosis who received Incivek combination therapy achieved SVR vs. 10 percent in the placebo group, OPDP pointed out

As it prepares for the readouts from a handful of clinical trials in the second half of the year, rare disease developer BioMarin Pharmaceutical Inc...In the SEC filings, BioMarin reported 116.5 million shares of common stock outstanding as of May 28

Oncomed had about 126.5 million shares of common stock outstanding on March 31...served as underwriters.

The company will issue 5.8 million shares of common stock and warrants to purchase 2.9 million shares of common stock...In addition to advancing the firm's clinical and lab-based stem cell research, the investment will help support the national expansion of its Regenexx Physician Network

Fourteen clinical trials support Supernus' application for SPN-538...Nine clinical trials support Supernus' application for SPN-804...LLC to sell its common stock with a value up to $40 million

is seeking to raise $40.5 million in an underwritten public offering of 4.5 million shares of common stock as the company turns its attention to TO-2061, a low-dose formulation of ondansetron as adjunctive treatment for obsessive compulsive disorder (OCD...Assuming that we succeed, of course, at that point we plan to sit down with the FDA to determine what they're going to want in the balance of the clinical program," Oclassen said

If this pivotal preclinical study pans out, we'll try to move into human clinical trials as soon as feasible," Marshall said...and a 2.5-year warrant to buy up to about 3.5 million shares of common stock at an exercise price of $1.18 per share...Rodman & Renshaw LLC acted as exclusive placement agent.

ArQule Inc., of Woburn, Mass., plans to sell 6 million shares of common stock in an underwritten public offering, which would bring in about $49 million based on Monday's closing price...Proceeds will be used for clinical trials, such as the Phase III trials of tivantinib in lung cancer, and for general corporate purposes

The company is splitting the cost of ocriplasmin's clinical development in additional indications, including age-related macular degeneration and diabetic retinopathy, on a 50/50 basis with Alcon...Each unit consists of one share of common stock and a warrant to purchase one share

The condition can vary in severity and has easily assessed markers of clinical benefit...Net proceeds totaling about $7.2 million will be used for general corporate purposes, including clinical trial expenses and R&D expenses...The funds will be used to develop PRX 302, a candidate for benign prostatic hyperplasia.

The shares will be converted into common stock immediately prior to the IPO's closing...The securities are subject to a four-month holding period.

It will use proceeds of approximately $86 million to complete clinical development of dalbavancin, to fund commercialization activities for the product in the U.S...Durata had 500,000 shares of common stock outstanding on Feb. 29, and 77,197,936 additional shares issuable upon automatic conversion of all series A preferred stock

Holders of the biotech's common stock and Series A warrants will be eligible to purchase one unit for each share of stock owned or issuable, with each unit consisting of one-half of a common share and a warrant to purchase an additional one-quarter of a common share...Proceeds will support clinical trials of cancer metabolism programs ME-344 and ME-143

Celldex Therapeutics Inc., of Needham, Mass., said underwriters of its public offering of common stock exercised in full their overallotment option to purchase an additional 1,575 million shares at $3.85 each...Celldex expects to use net proceeds from the offering, including the overallotment option, to fund clinical trials of its product candidates and for other corporate purposes

We're looking at the prevention of all the clinical signs associated with sickle cell disease – primarily the frequency of pain crises in these patients," Longenecker told BioWorld Today...The company issued Series G convertible preferred stock, without warrants, convertible into common stock at 40 cents per share

Those shares are convertible into common stock after March 8, 2017, at a rate of 1,000 common shares for one preferred share...Funds are expected to support ongoing business development and clinical efforts and for general corporate purposes

The data were presented last month at the 2012 American Society for Clinical Oncology Genitourinary Cancers Symposium...Enrollment in the Phase II portion of the study is complete, Heyman added, and clinical data are expected later this year...On Monday, the company's shares (OTCQB:ELTP) closed unchanged, at 10 cents.

LLC exercise their full overallotment option – are expected to support ongoing clinical development, particularly work on Amigal (migalastat HCl), which is in Phase III testing as a monotherapy for Fabry disease and in Phase II trials in combination with enzyme replacement therapy (ERT...TG Therapeutics Inc., of New York, said it closed a $25 million financing, with proceeds primarily going to support clinical development of ublituximab, a third-generation chimeric monoclonal antibody licensed from

Horizon Pharma Inc., of Deerfield, Ill., is bringing in $50.8 million in a private placement of about 14 million units – each comprising one share of common stock and a warrant to purchase 0.25 shares – priced at $3.62125 apiece...Proceeds are expected to fund R&D costs for the firm's Cell Pouch System, including the upcoming first clinical trial in diabetics receiving an islet transplant...Funds will be used to support ongoing drug development activities and for general corporate purposes and working